# The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

> **NCT02700464** · NA · COMPLETED · sponsor: **Nucleix Ltd.** · enrollment: 680 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DEVICE:** Bladder EpiCheck Urine Test
- **PROCEDURE:** Cystoscopy and pathology

## Key facts

- **NCT ID:** NCT02700464
- **Lead sponsor:** Nucleix Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2020-04
- **Final completion:** 2020-07
- **Target enrollment:** 680 (ACTUAL)
- **Last updated:** 2021-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02700464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02700464, "The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02700464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*